Antibiotic resistance fuels 87% of India's typhoid economic burden: Study
Typhoid fever is an infectious disease commonly transmitted through contaminated food or water. Symptoms can include high fever, fatigue, headache and stomach pain
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
A recent study in The Lancet reveals that antibiotic-resistant typhoid infections constitute 87% of India's total typhoid-related economic burden of ₹123 billion. The research highlights a significant public health crisis, where households bear 91% of the costs, and young children are disproportionately affected. This situation is primarily driven by resistance to fluoroquinolone, a key antibiotic, leading to prolonged illness and increased medical expenses.
UPSC Perspectives
Social
The study's findings are a stark illustration of Health Inequity and the Social Determinants of Health. Typhoid, a water-borne disease, thrives in conditions of inadequate sanitation and unsafe drinking water, which disproportionately affects lower-income communities. The report shows this inequity is compounded by antimicrobial resistance (AMR), where the most vulnerable, particularly children under 10, suffer the most. When households bear 91% of the financial burden, it leads to catastrophic health expenditure, defined as out-of-pocket health spending exceeding 10-25% of a household's total expenditure. This can push families into a vicious cycle of poverty and poor health, undermining the fundamental Right to Health implicitly guaranteed under of the Constitution. UPSC can frame questions on the interplay between public health infrastructure, poverty, and disease burden, asking how AMR exacerbates social inequalities.
Governance
This report reinforces the urgency for robust Public Health Policy interventions. The authors' call to introduce the (TCV) into the national immunization schedule is a critical point of analysis. While the article states this is 'under consideration', the TCV has already been recommended for inclusion and is being rolled out in phases under India's (UIP) with support from Gavi, the Vaccine Alliance. This highlights a partial gap between policy formulation and universal implementation. Furthermore, the study underscores the need to strengthen India's (NAP-AMR). The NAP-AMR advocates for a 'One Health' approach, integrating human, animal, and environmental health to control AMR. Challenges remain in its implementation, including regulatory enforcement on antibiotic sales, improving sanitation, and managing pharmaceutical waste. Mains questions could explore the effectiveness of India's public health response to AMR and the challenges in implementing the 'One Health' concept.
Economic
The study quantifies the significant Economic Burden of Disease imposed by AMR. The total cost of ₹123 billion, driven by fluoroquinolone resistance, represents a major drain on the economy, impacting both individual finances and national productivity through indirect costs like lost wages. The high Out-of-Pocket Expenditure (OOPE) is a critical concern, as it indicates low public health financing and inadequate insurance penetration. While schemes like (PM-JAY) aim to reduce OOPE by providing cashless cover for secondary and tertiary care, its effectiveness depends on the inclusion of specific treatment packages and the empanelment of hospitals. The report's findings on catastrophic expenditure suggest that existing safety nets may not be sufficient for prolonged treatments necessitated by AMR. UPSC could ask candidates to analyze the economic impact of AMR on India's goal of achieving Universal Health Coverage and suggest policy measures to strengthen health financing and reduce the burden of OOPE.